Cytokinetics, IncorporatedCYTKReports Wed, Nov 4 · Third Quarter 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · cytokinetics.com
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that discovers and develops muscle activators and inhibitors as potential treatments for debilitating diseases. Its cardiac muscle programs include aficamten for hypertrophic cardiomyopathy, evaluated in the ACACIA-HCM and MAPLE-HCM trials.
Key ratios
FCF / Sales
-607.5%2025
2024
-2164.1%2023
-5521.2%
ROA
-27.1%2025
2024
-30.1%2023
-33.7%
Revenue growth
376.6%2025
2024
145.3%2023
-92.0%
Recent news
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
Cytokinetics to Announce Third Quarter Results on November 4, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Track CYTK in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer